Takara BioFRA:TF2 74 Quick Ratio is 4.27 as of Mar. 2026, which is 12% below its 10-year median of 4.84. GuruFocus rates FRA:TF2 with a GF Score™ of 74/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,413 Biotechnology companies, Takara Bio ranks better than 54.56% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Takara Bio's quick ratio for the quarter that ended in Mar. 2026 was 4.27.
Takara Bio has a quick ratio of 4.27. It generally indicates good short-term financial strength.
The historical rank and industry rank for Takara Bio's Quick Ratio or its related term are showing as below:
FRA:TF2'
s Quick Ratio Range Over the Past 10 Years
Min: 2.54 Med: 4.84 Max: 7.1
Current: 4.27
During the past 13 years, Takara Bio's highest Quick Ratio was 7.10. The lowest was 2.54. And the median was 4.84.
FRA:TF2's Quick Ratio is ranked better than 54.56% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:TF2: 4.27
Takara Bio (FRA:TF2) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Takara Bio Quick Ratio Related Terms
Takara Bio Quick Ratio Historical Data
* Premium members only.
The historical data trend for Takara Bio's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Takara Bio's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Takara Bio's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Takara Bio's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takara Bio (FRA:TF2) has a Quick Ratio of 4.27 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Takara Bio and its competitors. This is 12% below median its historical median of 4.84. Over the past decade, Takara Bio's Quick Ratio has ranged from 2.54 to 7.10. According to the industry distribution chart, Takara Bio ranks #642 out of 1413 companies in the Biotechnology industry, placing it in the top 45.4%.
Is Takara Bio's Quick Ratio too high?
Takara Bio's current Quick Ratio of 4.27 is 12% below median its 10-year median of 4.84. Over the past 10 years, this metric has ranged from a low of 2.54 to a high of 7.10. The Biotechnology industry median Quick Ratio is 3.60. Takara Bio's value of 4.27 is 18.6% above this industry median. Based on the distribution chart, Takara Bio ranks #642 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Takara Bio has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #642 out of 1413 companies for Quick Ratio. This puts Takara Bio in the upper half of its industry. The industry median Quick Ratio is 3.60. Takara Bio's value of 4.27 is 18.6% above this benchmark. Historically, Takara Bio's own Quick Ratio has ranged from 2.54 to 7.10 over the past decade. While the company's 10-year median is 4.84 vs. the industry median of 3.60, Takara Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takara Bio's current Quick Ratio of 4.27 is 18.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current Quick Ratio is 4.27, which is 12% below median its own 10-year median of 4.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €5.95 — trading 33.4% above its estimated fair value. The current Quick Ratio is 4.27, which is 12% below median its 10-year median of 4.84 and 18.6% above the Biotechnology industry median of 3.60. Takara Bio's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Quick Ratio is 4.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.4% above its estimated GF Value™ of €4.46.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
Quick Ratio: 4.27 (12% below median its 10-year median of 4.84)
GF Value™: €4.46 vs. price of €5.95 (33.4% above fair value)
Industry Position: 18.6% above the Biotechnology median (#642 of 1413)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
74GF Score
Get the complete analysis for FRA:TF2
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
